MX2017003832A - Metodo para la prediccion de sensibilidad a un tratamiento con un inhibidor de egfr. - Google Patents
Metodo para la prediccion de sensibilidad a un tratamiento con un inhibidor de egfr.Info
- Publication number
- MX2017003832A MX2017003832A MX2017003832A MX2017003832A MX2017003832A MX 2017003832 A MX2017003832 A MX 2017003832A MX 2017003832 A MX2017003832 A MX 2017003832A MX 2017003832 A MX2017003832 A MX 2017003832A MX 2017003832 A MX2017003832 A MX 2017003832A
- Authority
- MX
- Mexico
- Prior art keywords
- egfr
- egfr inhibitor
- patient
- relates
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14306490.5A EP3000895A1 (en) | 2014-09-26 | 2014-09-26 | A method for predicting responsiveness to a treatment with an EGFR inhibitor |
| PCT/EP2015/072095 WO2016046365A1 (en) | 2014-09-26 | 2015-09-25 | A method for predicting responsiveness to a treatment with an egfr inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017003832A true MX2017003832A (es) | 2018-02-23 |
Family
ID=51663116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017003832A MX2017003832A (es) | 2014-09-26 | 2015-09-25 | Metodo para la prediccion de sensibilidad a un tratamiento con un inhibidor de egfr. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20170298442A1 (https=) |
| EP (2) | EP3000895A1 (https=) |
| JP (1) | JP2017529852A (https=) |
| KR (1) | KR20170086469A (https=) |
| CN (1) | CN107075583A (https=) |
| AU (1) | AU2015323744A1 (https=) |
| BR (1) | BR112017005421A2 (https=) |
| CA (1) | CA2961434A1 (https=) |
| MX (1) | MX2017003832A (https=) |
| WO (1) | WO2016046365A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2749651T3 (es) | 2015-02-11 | 2020-03-23 | Region Midtjylland | Método basado en microARN para la detección temprana de cáncer de próstata en muestras de orina |
| ES2724404T3 (es) * | 2015-02-27 | 2019-09-10 | Qiagen Gmbh | Un procedimiento basado en microARN para evaluar el pronóstico de un paciente de cáncer de próstata |
| CN108034727B (zh) * | 2018-01-18 | 2021-05-28 | 四川大学华西医院 | 检测MicroRNA-31-5p表达水平的试剂在制备肿瘤靶向药敏感性检测试剂盒中的用途 |
| KR102480430B1 (ko) * | 2020-10-21 | 2022-12-21 | 순천향대학교 산학협력단 | 주사증 진단을 위한 마이크로RNA-31-5p 및 이의 용도 |
| CN119303090B (zh) * | 2024-10-15 | 2025-06-20 | 中国医学科学院北京协和医院 | miR-210-3p和/或miR-31-5p在薄型子宫内膜中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2439402A1 (en) | 2001-03-02 | 2002-09-12 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Pcr method |
| WO2009080437A1 (en) | 2007-12-21 | 2009-07-02 | Exiqon A/S | Micro-rna based drug resistance analysis method |
| US20120095030A1 (en) | 2009-04-17 | 2012-04-19 | The Translational Genomics Research Institute | Methods and kits to predict therapeutic outcome of tyrosine kinase inhibitors |
| MX2011013578A (es) * | 2009-06-19 | 2012-01-20 | Merck Patent Gmbh | Biomarcadores y metodos para determinar la eficacia de anticuerpos anti-receptor del factor de crecimiento epidermal (anti-egfr) en terapia de cancer. |
| CA2800557A1 (en) | 2010-04-29 | 2011-11-03 | Medical Prognosis Institute A/S | Methods and devices for predicting treatment efficacy |
| CA2856594A1 (en) | 2011-11-25 | 2013-05-30 | Integragen | A method for predicting responsiveness to a treatment with an egfr inhibitor |
| CN104046679B (zh) * | 2013-03-11 | 2016-08-24 | 戴勇 | 原发性IgA肾病肾脏组织差异表达miRNA的分析方法和应用 |
-
2014
- 2014-09-26 EP EP14306490.5A patent/EP3000895A1/en not_active Withdrawn
-
2015
- 2015-09-25 CA CA2961434A patent/CA2961434A1/en not_active Abandoned
- 2015-09-25 KR KR1020177009944A patent/KR20170086469A/ko not_active Withdrawn
- 2015-09-25 US US15/513,223 patent/US20170298442A1/en not_active Abandoned
- 2015-09-25 EP EP15767530.7A patent/EP3198028B1/en not_active Not-in-force
- 2015-09-25 AU AU2015323744A patent/AU2015323744A1/en not_active Abandoned
- 2015-09-25 BR BR112017005421A patent/BR112017005421A2/pt not_active IP Right Cessation
- 2015-09-25 CN CN201580051832.9A patent/CN107075583A/zh active Pending
- 2015-09-25 JP JP2017516368A patent/JP2017529852A/ja not_active Withdrawn
- 2015-09-25 WO PCT/EP2015/072095 patent/WO2016046365A1/en not_active Ceased
- 2015-09-25 MX MX2017003832A patent/MX2017003832A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017005421A2 (pt) | 2017-12-12 |
| WO2016046365A1 (en) | 2016-03-31 |
| KR20170086469A (ko) | 2017-07-26 |
| EP3198028B1 (en) | 2018-12-12 |
| US20170298442A1 (en) | 2017-10-19 |
| EP3198028A1 (en) | 2017-08-02 |
| AU2015323744A1 (en) | 2017-04-27 |
| EP3000895A1 (en) | 2016-03-30 |
| CA2961434A1 (en) | 2016-03-31 |
| CN107075583A (zh) | 2017-08-18 |
| JP2017529852A (ja) | 2017-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125190T1 (el) | Χρηση ομαδων γονιδιων fgfr μεταλλαγματων στην εξακριβωση του εαν καρκινοπαθεις θα αποκρινονται σε αγωγη me fgfr αναστολεα | |
| MX2016006782A (es) | Un metodo para predecir la capacidad de respuesta a un tratamiento con un inhibidor del egfr. | |
| MX2022006075A (es) | Antagonistas de union a pd-l1 y usos de los mismos para el tratamiento de cancer. | |
| MX2014006182A (es) | Un metodo para pronosticar reactividad a un tratamiento con un inhibidor de egfr. | |
| MX2017003832A (es) | Metodo para la prediccion de sensibilidad a un tratamiento con un inhibidor de egfr. | |
| PH12019501942A1 (en) | Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor | |
| JOP20190280A1 (ar) | مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية | |
| MX2024001734A (es) | Metodo de modificacion de diferenciacion e inmunidad de macrofagos. | |
| EA201790211A1 (ru) | Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака | |
| WO2017214373A8 (en) | Diagnostic and therapeutic methods for cancer | |
| WO2015158890A3 (en) | Pancreatic cancer therapy and diagnosis | |
| MX384423B (es) | Biomarcadores para la respuesta a inhibidores del mejorador del homólogo 2 de zeste (ezh2). | |
| MA40636A (fr) | Procédés pour détecter le cancer de la prostate | |
| EP4265740A3 (en) | Methods for predicting risk of metastasis in cutaneous melanoma | |
| MX2016008778A (es) | Deteccion de acidos nucleicos de entamoeba. | |
| EP3640643A3 (en) | Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer by measuring the level of a plasma biomarker | |
| MX2020006876A (es) | Procedimiento en curso para dirigir medidas contra la propagacion de salmonella y/o contra la propagacion de campylobacter en una manada de animales. | |
| EA201501137A1 (ru) | Биомаркеры генной экспрессии и их использование для диагностического и прогностического применения у пациентов, потенциально нуждающихся в лечении ингибитором hdac | |
| WO2015157624A3 (en) | A novel isoform of anaplastic lymphoma kinase and its uses | |
| EA202190962A2 (ru) | Уровни экспрессии иммуноглобулинов в качестве биологического маркера для реакции на ингибитор протеасом | |
| GB2553736A (en) | Method for identification of a deficient BRCA1 function | |
| HK1249555A1 (zh) | 通过检测微小rna(mirna)的表达水平来确定患乳腺癌的风险的方法 | |
| UA93433U (uk) | Спосіб визначення оксидантно-антиоксидантної системи крові за умов водного та сольового навантаження | |
| UA106708U (uk) | Спосіб прогнозування зрощення перелому | |
| UA95581U (uk) | Спосіб прогнозування зрощення перелому |